4.2 Review

Endocannabinoid metabolism by cytochrome P450 monooxygenases

Journal

PROSTAGLANDINS & OTHER LIPID MEDIATORS
Volume 116, Issue -, Pages 112-123

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.prostaglandins.2014.11.002

Keywords

Endocannabinoids; Cytochrome P450s; Anandamide; 2-Arachidonylglycerol; Eicosanoids; CYP2J2

Funding

  1. American Heart Association
  2. Molecular and Cellular Biology summer fellowship

Ask authors/readers for more resources

The endogenous cannabinoid system was first uncovered following studies of the recreational drug Cannabis sativa. It is now recognized as a vital network of signaling pathways that regulate several physiological processes. Following the initial discovery of the cannabinoid receptors 1 (CB1) and 2 (CB2), activated by Cannabis-derived analogs, many endogenous fatty acids termed endocannabinoids are now known to be partial agonists of the CB receptors. At present, the most thoroughly studied endocannabinoid signaling molecules are anandamide (AEA) and 2-arachidonylglycerol (2-AG), which are both derived from arachidonic acid. Both AEA and 2-AG are also substrates for the eicosanoid-synthesizing pathways, namely, certain cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) enzymes. In the past, research in the endocannabinoid field focused on the interaction of AEA and 2-AG with the COX and LOX enzymes, but accumulating evidence also points to the involvement of CYPs in modulating endocannabinoid signaling. The focus of this review is to explore the current understanding of CYP-mediated metabolism of endocannabinoids. (C) 2014 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available